Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. (PHAT) filed this Form 8-K on August 19, 2024, to report the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Offering Details
- Common Stock Issuance: 8,695,652 shares at an offering price of $11.50 per share.
- Pre-Funded Warrants: 2,608,922 warrants issued to certain investors at $11.499 per warrant (exercise price of $0.001).
- Expected Net Proceeds: Approximately $121.7 million before deducting underwriting discounts, commissions, and estimated offering expenses.
- Expected Closing Date: August 20, 2024, subject to customary closing conditions.
- Underwriters: Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC.
Material Changes and Terms
This filing represents a material capital event involving the issuance of new equity securities. The pre-funded warrants are immediately exercisable and do not expire. However, they are subject to a beneficial ownership limitation of 19.99% (or a lower percentage elected by the holder). Holders may adjust this percentage, provided any increase is not effective until 61 days after notice is delivered. The offering is conducted under the company's effective shelf registration statement on Form S-3.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion of the offering and expected net proceeds. Management cautions that actual results may differ due to market conditions and the satisfaction of closing conditions. The company explicitly states it undertakes no obligation to revise or update these forward-looking statements. No specific operational guidance or revenue outlook is provided in this document.
Investor Verification Checklist
- Verify the final closing of the offering on or after August 20, 2024.
- Confirm the actual net proceeds after deducting underwriting discounts and offering expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Form of Pre-Funded Warrant (Exhibit 4.1) for specific covenants and limitations.
- Monitor the company's cash position post-closing to assess runway for clinical development.